• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Immune Thrombocytopenic Purpura (ITP) - Pipeline Review, Q2 2011 - Product Image

Immune Thrombocytopenic Purpura (ITP) - Pipeline Review, Q2 2011

  • Published: April 2011
  • 79 pages
  • Global Markets Direct

Immune Thrombocytopenic Purpura (ITP) - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Immune Thrombocytopenic Purpura (ITP) - Pipeline Review, Q2 2011', provides an overview of the Immune Thrombocytopenic Purpura (ITP) therapeutic pipeline. This report provides information on the therapeutic development for Immune Thrombocytopenic Purpura (ITP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Immune Thrombocytopenic Purpura (ITP). 'Immune Thrombocytopenic Purpura (ITP) - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Immune Thrombocytopenic READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Immune Thrombocytopenic Purpura (ITP) Overview
Therapeutics Development
An Overview of Pipeline Products for Immune Thrombocytopenic Purpura (ITP)
Immune Thrombocytopenic Purpura (ITP) Therapeutics under Development by Companies
Immune Thrombocytopenic Purpura (ITP) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Immune Thrombocytopenic Purpura (ITP) Therapeutics - Products under Development by Companies
Immune Thrombocytopenic Purpura (ITP) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Immune Thrombocytopenic Purpura (ITP) Therapeutics Development
AstraZeneca PLC
GlaxoSmithKline plc
Symphogen A/S
Eisai Co., Ltd.
IMMUNOMEDICS, INC
Maywufa Company Limited
Bio Products Laboratory
SuppreMol GmbH
Immune Thrombocytopenic Purpura (ITP) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Veltuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E5501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sym001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LGD-4665 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHN013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan + Cyclophosphamide + Vincristine + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + MabThera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gammaplex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R788 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone USP Micronized - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Daclizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SM101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IVIG + Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-D - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bu Zhong Yi Qi Wan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zhi Xue Tang - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chuan Xin Lian Kang Yan Pian Mod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tian Wang Bu xin Dan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bu Zhong Yi Qi Tang + Zhi Xue Tang + Chuan xin lian kang yan pian mod + Tian Wang Bu xin Dan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IGIV3I Grifols - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Immune Thrombocytopenic Purpura (ITP) Therapeutics – Drug Profile Updates
Immune Thrombocytopenic Purpura (ITP) Therapeutics - Discontinued Products
Immune Thrombocytopenic Purpura (ITP) - Featured News
Mar 16, 2011: NICE Gives Green Light To Romiplostim In Chronic Immune Thrombocytopenic Purpura
Feb 25, 2011: GlaxoSmithKline Receives FDA Approval For PROMACTA For Treatment Of Rare Blood Disorder
Jan 24, 2011: SuppreMol Completes Successful Pre-IND Meeting With FDA For Lead Compound SM101
Dec 05, 2010: Amgen's Nplate Maintains Platelet Counts For More Than Five Years In Adults With Chronic Idiopathic Thrombocytopenic Purpura
Nov 10, 2010: Amgen Announces Publication Of Chronic ITP Study With Nplate In New England Journal Of Medicine
Nov 02, 2010: Ligand Announces Approval Of Revolade In Japan
Oct 06, 2010: Symphogen And Swedish Orphan Biovitrum Receive US Orphan Drug Designation For Rozrolimupab In Immune Thrombocytopenia
Sep 24, 2010: Octapharma Publishes Convincing Study Results On Octagam 10% In Hematology
Apr 19, 2010: SuppreMol Receives U.S. Orphan Drug Designation For SM101
Feb 16, 2010: AstraZeneca Signs Agreement With Rigel Pharmaceuticals For Fostamatinib Disodium (R788)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Immune Thrombocytopenic Purpura (ITP), Q2 2011
Products under Development for Immune Thrombocytopenic Purpura (ITP) – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
AstraZeneca PLC, 2011
GlaxoSmithKline plc, 2011
Symphogen A/S, 2011
Eisai Co., Ltd., 2011
IMMUNOMEDICS, INC, 2011
Maywufa Company Limited, 2011
Bio Products Laboratory, 2011
SuppreMol GmbH, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Immune Thrombocytopenic Purpura (ITP) Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Immune Thrombocytopenic Purpura (ITP), Q2 2011
Products under Development for Immune Thrombocytopenic Purpura (ITP) – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos